172927-134x178.jpg

March/April 2015

Volume 16, Issue 2

 

Browse other issues »Subscribe to our print issues »

Articles in this Issue

  • What to Look for in Selecting a CRO/CMO and How to Ensure the Right Choice: A Quality Assurance...

    Amer Alghabban
    Outsourcing used to be done for mostly “non-critical products/services,” but the last 20 years have seen a reversal in this trend. More and more companies are outsourcing key critical Good X Practices (GxP)-regulated clinical processes and products manufacturing.
  • Clinical Materials: Changes and Comparability

    Jilla K. Boulas, MS
    The development of a drug product is a long and costly journey which starts from basic research and moves down a path that requires much development, and takes turns at points where decisions have to be made. At the end of this path, one hopes to arrive at a safe and effective product for the treatment or prevention of a disease or condition.
  • Solubility in Pharmaceutical R&D: Predictions and Reality

    David P. Elder, Ph.D., Christoph Saal, PhD
    Lipinski’s seminal paper on experimental and computational (in silico) methods to estimate the solubility and permeability of drug candidates was published in 1997. The iconic “Rule of 5” predicted that absorption was adversely impacted when the calculated LogP (cLogP) was >5, when molecular weight (MW) was >500, when there are >5 H-bond donors or >10 H-bond acceptors.
  • Potential Contribution of a Plasticized PVC Packaging Material to the Level of Elemental Impurities...

    Dennis Jenke, Ph.D., Barrett E. Rabinow, Molly Chacko
    Extraneous impurities in a drug product do not provide a therapeutic benefit to the product’s user and could adversely impact the safety and/or efficacy of the drug product. An important set of impurities (known as elemental impurities) are those entities, organic or inorganic, whose chemical formulae include elements from the following series in the periodic table: transition metals, metalloids, other metals, and lanthanides and actinides.
  • HORIZON LINES: A Quarterly Review of NDAs - 2Q14

    Harshada Sant, MS, Hemant N. Joshi, Ph.D., MBA
    This column summarizes New Drug Applications (NDAs) for the third quarter 2014 (July through September 2014). In this quarter, FDA approved 38 NDAs.
  • Patient Focus: The Heart of Biopharmaceutical R&D

    J. Michael Maher, MS, MBA
    Successful companies are customer-focused, and in the research-based pharmaceutical industry, patients are the key customer. The biopharmaceutical industry is unique in many ways, however, with attributes that complicate the straightforward consumer-provider relationship enjoyed by many other businesses.
  • Today's Special in Clinical Trials: Risk-Based Monitoring. Have Investigators Been Served?

    Eduardo F. Motti, M.D.
    Many readers may agree that Brazil is the country of soccer (until its recent loss to Germany by 7 to 1 in the 2014 World Cup). Brazil's famous association with soccer galvanized after it won the 1958 World Cup in Sweden and introduced 2 phenomenal players: Pelé and Garrincha. The latter did not become as internationally famous as Pelé, but he was a soccer genius, too, in spite of several significant physical and intellectual limitations.
  • Technological Capabilities and Scientific Expertise Are Top Criteria in Pharmaceutical Outsourcing...

    Lea Studer
    Contract manufacturing is playing an increasingly important role in the strategic approach companies ranging from big pharma to specialized biotech take in producing products for sale.
  • <<
  • >>